DTRM Biopharma is a clinical-stage biopharmaceutical company developing first-in-class, fixed-dose combination (FDC), low dose, oral therapies to treat cancers and immune diseases including rare diseases with global patent protections.
The innovative paradigm-shifting therapies in a few years are designed to turn terminal cancers into chronically manageable diseases, the same as today’s treatments for Acquired Immune Deficiency Syndrome (AIDS), Hepatitis C Virus (HCV) that have taken decades for their clinical developments.
DTRM Biopharma is executing its precision medicine development with US Leadership Team, who have decades of experience and expertise with a proven track record, with the China Core Team. Its patient-focused, US-centric, simultaneous development in the US and China are unique among emerging biopharma companies in the World.
Main Products are Double Combination DTRM-505 FDC tablets, Triple Combination DTRM-555 FDC tablets, and Triple Combination DTRM-321 FDC tablets with clinically differentiated BTK Inhibitor DTRMWXHS-12 as the backbone and one of the key ingredients for the low-dose, once daily, FDC therapies.